The Manufacturers Life Insurance Company Sells 3,078 Shares of Insulet Corporation $PODD

The Manufacturers Life Insurance Company trimmed its stake in Insulet Corporation (NASDAQ:PODD) by 7.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,619 shares of the medical instruments supplier’s stock after selling 3,078 shares during the period. The Manufacturers Life Insurance Company’s holdings in Insulet were worth $7,684,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Insulet during the 4th quarter worth approximately $26,000. DV Equities LLC bought a new position in Insulet during the 4th quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new position in shares of Insulet in the 4th quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the fourth quarter valued at $29,000.

Analyst Ratings Changes

A number of brokerages have weighed in on PODD. Canaccord Genuity Group decreased their price target on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. TD Cowen lowered their price objective on shares of Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a research note on Monday, June 1st. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Finally, Stifel Nicolaus cut their target price on shares of Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $233.38.

Insulet Trading Down 1.7%

PODD opened at $166.82 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The firm has a market capitalization of $11.55 billion, a PE ratio of 38.80, a P/E/G ratio of 1.18 and a beta of 1.10. The company’s 50-day moving average is $155.82 and its 200 day moving average is $196.09.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the company earned $1.02 earnings per share. As a group, research analysts predict that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Insulet is scheduled to report second-quarter 2026 results shortly, making the upcoming earnings release a key near-term catalyst. Investors will likely focus on Omnipod product quality, manufacturing remediation, demand, and management’s outlook. Insulet Q2 2026 Earnings Preview
• Negative Sentiment: A federal securities class action was filed against Insulet and certain officers on behalf of investors who purchased securities during periods ranging from February 21 or May 21, 2025, through May 26, 2026. The allegations center on potentially misleading statements about Omnipod manufacturing quality and product safety; the claims have not been proven in court. Investors have until August 31, 2026, to seek appointment as lead plaintiff. Pomerantz class-action announcement
• Negative Sentiment: Investor-law-firm notices link the lawsuit to two Omnipod medical-device corrections and allege that the issues revealed broader quality-control problems, contributing to a decline of more than 6% in the stock and a reported roughly $90-per-share loss from prior optimism. The growing number of legal solicitations increases reputational, financial, and litigation risks for Insulet. Insulet stock-drop and class-action notice

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.